J Ryan Petrulli1, Søren B Hansen2, Galith Abourbeh3, Maqsood Yaqub4, Idris Bahce5, Daniel Holden6, Yiyun Huang6, Nabeel B Nabulsi6, Joseph N Contessa7, Eyal Mishani8, Adriaan A Lammertsma9, Evan D Morris10. 1. Department of Biomedical Engineering, Yale University, New Haven, CT, United States; Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, United States. 2. Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. 3. Hadassah Cyclotron Unit, Hadassah Medical Center, Jerusalem, Israel. 4. Department of Radiology, VU University Medical Center, Amsterdam, Netherlands. 5. Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, Netherlands. 6. Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, United States. 7. Department of Therapeutic Radiology, Yale University, New Haven, CT, United States. 8. Hadassah Nuclear Medicine Institute, Hadassah Medical Center, Jerusalem, Israel. 9. Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, Netherlands. 10. Department of Biomedical Engineering, Yale University, New Haven, CT, United States; Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, United States. Electronic address: evan.morris@yale.edu.
Abstract
INTRODUCTION: Erlotinib is a tyrosine kinase inhibitor prescribed for non-small cell lung cancer (NSCLC) patients bearing epidermal growth factor receptor mutations in the kinase domain. The objectives of this study were to (1) establish a human dosimetry profile of [11C]erlotinib and (2) assess the consistency of calculated equivalent dose across species using the same dosimetry model. METHODS: Subjects examined in this multi-species study included: a stage IIIa NSCLC patient, 3 rhesus macaque monkeys, a landrace pig, and 4 athymic nude-Fox1nu mice. [11C]erlotinib PET data of the whole body were acquired dynamically for up to 120min. Regions of interest (ROIs) were manually drawn to extract PET time activity curves (TACs) from identifiable organs. TACs were used to calculate time-integrated activity coefficients (residence times) in each ROI, which were then used to calculate the equivalent dose in OLINDA. Subject data were used to predict the equivalent dose to the organs of a 73.7kg human male. RESULTS: In three of four species, the liver was identified as the organ receiving the highest equivalent dose (critical organ). The mean equivalent doses per unit of injected activity to the liver based on human, monkey, and mouse data were 29.4μSv/MBq, 17.4±6.0μSv/MBq, and 5.27±0.25μSv/MBq, respectively. The critical organ based on the pig data was the gallbladder wall (20.4μSv/MBq) but the liver received a nearly identical equivalent dose (19.5μSv/MBq). CONCLUSIONS: (1) When designing PET studies using [11C]erlotinib, the liver should be considered the critical organ. (2) In organs receiving the greatest equivalent dose, mouse data underestimated the dose in comparison to larger species. However, the effective dose of [11C]erlotinib to the whole body of a 73.7kg man was predicted with good consistency based on mice (3.14±0.05μSv/MBq) or the larger species (3.46±0.25μSv/MBq).
INTRODUCTION:Erlotinib is a tyrosine kinase inhibitor prescribed for non-small cell lung cancer (NSCLC) patients bearing epidermal growth factor receptor mutations in the kinase domain. The objectives of this study were to (1) establish a human dosimetry profile of [11C]erlotinib and (2) assess the consistency of calculated equivalent dose across species using the same dosimetry model. METHODS: Subjects examined in this multi-species study included: a stage IIIa NSCLCpatient, 3 rhesus macaque monkeys, a landrace pig, and 4 athymic nude-Fox1nu mice. [11C]erlotinib PET data of the whole body were acquired dynamically for up to 120min. Regions of interest (ROIs) were manually drawn to extract PET time activity curves (TACs) from identifiable organs. TACs were used to calculate time-integrated activity coefficients (residence times) in each ROI, which were then used to calculate the equivalent dose in OLINDA. Subject data were used to predict the equivalent dose to the organs of a 73.7kg human male. RESULTS: In three of four species, the liver was identified as the organ receiving the highest equivalent dose (critical organ). The mean equivalent doses per unit of injected activity to the liver based on human, monkey, and mouse data were 29.4μSv/MBq, 17.4±6.0μSv/MBq, and 5.27±0.25μSv/MBq, respectively. The critical organ based on the pig data was the gallbladder wall (20.4μSv/MBq) but the liver received a nearly identical equivalent dose (19.5μSv/MBq). CONCLUSIONS: (1) When designing PET studies using [11C]erlotinib, the liver should be considered the critical organ. (2) In organs receiving the greatest equivalent dose, mouse data underestimated the dose in comparison to larger species. However, the effective dose of [11C]erlotinib to the whole body of a 73.7kg man was predicted with good consistency based on mice (3.14±0.05μSv/MBq) or the larger species (3.46±0.25μSv/MBq).
Authors: K Wienhard; M Dahlbom; L Eriksson; C Michel; T Bruckbauer; U Pietrzyk; W D Heiss Journal: J Comput Assist Tomogr Date: 1994 Jan-Feb Impact factor: 1.826
Authors: Maqsood Yaqub; Idris Bahce; Charlotte Voorhoeve; Robert C Schuit; Albert D Windhorst; Otto S Hoekstra; Ronald Boellaard; N Harry Hendrikse; Egbert F Smit; Adriaan A Lammertsma Journal: J Nucl Med Date: 2016-02-04 Impact factor: 10.057
Authors: Idris Bahce; Egbert F Smit; Mark Lubberink; Astrid A M van der Veldt; Maqsood Yaqub; Albert D Windhorst; Robert C Schuit; Erik Thunnissen; Daniëlle A M Heideman; Pieter E Postmus; Adriaan A Lammertsma; N Harry Hendrikse Journal: Clin Cancer Res Date: 2012-11-07 Impact factor: 12.531
Authors: Antonia Högnäsbacka; Alex J Poot; Danielle J Vugts; Guus A M S van Dongen; Albert D Windhorst Journal: Pharmaceuticals (Basel) Date: 2022-04-05
Authors: Koen Van Laere; Michel Koole; Christopher Cawthorne; Paul Maguire; Joel Mercier; David Sciberras; Kim Serdons; Guy Bormans; Jan de Hoon Journal: EJNMMI Phys Date: 2021-04-23